Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing To Power The Next Era Of Dna-Enabled Industries
Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing To Power The Next Era Of Dna-Enabled Industries
04/11/22, 12:00 PM
Money raised
$68 million
Round Type
series a
Ansa Biotechnologies today announced it has closed an oversubscribed Series A financing round of $68 million led by Northpond Ventures, with participation from new investors RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital, and existing investors Mubadala Capital, Humboldt Fund, Fifty Years, and Horizons Ventures. The company has raised a total of $82 million from private financings to date.
Company Info
Company
Ansa Biotechnologies
Additional Info
Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods. For more information, visit ansabio.com or follow on Twitter and LinkedIn.